Why the study?
Does the addition of antiplatelet therapy to VKA therapy reduce recurrent coronary events or thromboembolism in atrial fibrillation patients with stable coronary artery disease?
Does the addition of antiplatelet therapy to VKA therapy reduce recurrent coronary events or thromboembolism in atrial fibrillation patients with stable coronary artery disease?
Adding antiplatelet therapy to VKA anticoagulation in AF patients with stable CAD increases bleeding risk without reducing coronary or thromboembolic events, suggesting this common practice should be reassessed.
Answers are grounded in this paper and cite their sources.
No event reduction but higher bleeding with added antiplatelet to VKA in AF with stable CAD; leaves open whether RCTs will alter practice.
In atrial fibrillation patients with stable coronary artery disease, the addition of antiplatelet therapy to VKA therapy is not associated with a reduction in risk of recurrent coronary events or thromboembolism, whereas risk of bleeding is increased significantly. The common practice of adding antiplatelet therapy to oral VKA anticoagulation in patients with atrial fibrillation and stable coronary artery disease warrants reassessment.
No takes yet. Share an insight, caveat, or question.
Lamberts et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: